VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- TRIUMF, Canada’s particle accelerator centre, and General Fusion, an international leader in the development of commercial fusion energy, have received a Natural Sciences and Engineering Research Council of Canada (NSERC) Alliance grant to advance technology critical to measuring extreme temperatures inside a fusion machine. Grant funding of $800,000 over four years will support the design and delivery of an ultra-fast neutron spectrometer system to measure plasma temperatures at fusion conditions of over 100 million degrees Celsius (10 keV), a key technical milestone that General Fusion aims to achieve at large scale by 2025.
The neutron spectrometer system is a flagship project under the collaborative agreement signed by TRIUMF and General Fusion in 2023. Known for pushing the boundaries of science and innovation, TRIUMF will support General Fusion in developing a diagnostic system capable of precisely measuring neutron energies at a very high rate. Neutrons carry unique information about fusion reactions, and the system being built at TRIUMF and General Fusion will tag neutron interactions every nanosecond.
The highly advanced spectrometer will debut on General Fusion’s new Lawson Machine 26 (LM26) fusion demonstration machine to measure ion temperature, a critical plasma parameter, at peak compression of a magnetized plasma. Following LM26 operations, the company expects to upgrade the system for its planned near-commercial machine. To further support this trailblazing diagnostic work over the next four years, TRIUMF and General Fusion have enlisted experts from Simon Fraser University to design and implement a dedicated neutron test facility. Additionally, at the Université de Sherbrooke in Quebec, new Canadian single photon detection technology is being further developed and fabricated for the upgraded system that will be installed on General Fusion’s near-commercial machine.
“This exciting project highlights the deep technology collaboration happening across the country to advance Canadian fusion energy technology,” said Greg Twinney, CEO, General Fusion. “Together with top labs and universities, we are building and testing world-leading systems required to deliver commercial fusion energy to the grid by the early to mid-2030s.”
“This is a prime example of how TRIUMF expertise and infrastructure impact our world,” commented Kathryn Hayashi, CEO of TRIUMF Innovations, TRIUMF’s commercialization arm. “TRIUMF Innovations’ project with General Fusion uses our research and development work to fill a technology gap in high-rate neutron detection and provides potential for direct market outcomes in clean fusion energy, healthcare, and subatomic physics applications.”
About TRIUMF
Established in 1968 in Vancouver, TRIUMF is Canada’s particle accelerator centre. The lab is a hub for discovery and innovation inspired by a half-century of ingenuity in answering some of nature’s most challenging questions. From the hunt for the smallest particles in our universe and the origin of the elements that make up our world to research that advances the next generation of batteries, quantum computers or cures for cancer, TRIUMF is pushing frontiers in research, while training the next generation of leaders in science, medicine, and industry.
TRIUMF Media Relations
Stu Shepherd
Head, Communications
1.604.222.7528
sshepherd@triumf.ca
@TRIUMFLab
About General Fusion
General Fusion is pursuing a fast and practical approach to commercial fusion energy and is headquartered in Richmond, B.C., Canada. The company was established in 2002 and is funded by a global syndicate of leading energy venture capital firms, industry leaders, and technology pioneers. Learn more at www.generalfusion.com.
General Fusion Media Relations
media@generalfusion.com
+1-866-904-0995
Follow General Fusion
twitter.com/generalfusion
instagram.com/generalfusion
linkedin.com/company/general-fusion
facebook.com/generalfusion
youtube.com/c/GeneralFusionInc
-
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cVANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a di2024-06-17
-
Indonesia Stock Exchange Partners with Nasdaq to Upgrade Market InfrastructureTechnology partnership will further enhance overall resilience and integrity of the exchange, while supporting the rapid deployment of new products2024-06-17
-
Adalvo 的 Liraglutide 預充式注射筆成為歐盟首款獲得批准的仿製藥馬爾他聖瓜安, June 17, 2024 (GLOBE NEWSWIRE) -- Adalvo 宣布 Liraglutide 預充式注射筆成功取得 DCP 批准,成為歐盟首款獲得批准的仿製藥。 根據 IQVIA 的報2024-06-17
-
促进生育,助力三胎——“三胎免费生”联合公益行动正式启动为积极响应国家号召实施三胎生育政策,扩大妇幼服务健康供给,在云南省优生优育妇幼保健协会指导下,昆明广播电视台联合昆明安琪儿妇产医院,于6月13日在昆明广播2024-06-17
-
学党史传承红色精神 守党纪筑牢自律防线——平安养老险湖南分公司党支部开展主题党日活动七一前夕,平安养老险湖南分公司党支部全体成员走进“千年学府、百年师范”——湖南第一师范,开展了一次学史明理、学史增信、学史崇德、学史力行的主题党日活动。重2024-06-17